BCW-Based Resistance Training for Community-Dwelling Sarcopenia Patients (BCW-RES)
Effects of a Behavior Change Wheel (BCW)-Based Resistance Exercise Program on Community-Dwelling Patients With Sarcopenia: A Randomized Controlled Trial
調査の概要
詳細な説明
Sarcopenia is a progressive and generalized skeletal muscle disorder that significantly impairs physical function and quality of life in older adults. While resistance exercise is a well-established countermeasure, poor long-term exercise adherence remains a critical clinical barrier. To address this, the current study utilizes the Behavior Change Wheel (BCW) theory to construct a structured, theory-driven resistance exercise program aimed at enhancing both physiological health and behavioral compliance.
This study employs a randomized, waitlist-controlled trial design to ensure ethical equity, allowing all participants to eventually benefit from the intervention. Eligible community-dwelling older adults with sarcopenia will be randomly assigned to either an experimental group or a waitlist control group. The experimental group will immediately commence a 12-week BCW-based resistance exercise intervention (conducted twice weekly). The waitlist control group will undergo a 3-month observation period with their usual routine, after which they will cross over to receive the identical 12-week exercise program.
To comprehensively evaluate the efficacy of the intervention, primary and secondary outcomes-encompassing structural muscle health, physical performance, psychological indicators (e.g., self-efficacy, quality of life), and patient satisfaction-will be rigorously assessed at baseline, at 3 months, and post-intervention.
研究の種類
段階
- 適用できない
連絡先と場所
研究場所
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国
- Tianshui Wulin Sub-district Community Health Service Center
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
Meet the diagnostic criteria for sarcopenia according to the Asian Working Group for Sarcopenia (AWGS) 2025:
Low muscle mass (SMI measured by BIA): For age ≥ 65, Male < 7.0 kg/m², Female < 5.7 kg/m²; For age 50-64, Male < 7.6 kg/m², Female < 5.7 kg/m².
Low muscle strength (Handgrip strength): For age ≥ 65, Male < 28 kg, Female < 18 kg; For age 50-64, Male < 34 kg, Female < 20 kg.
Ability to walk independently without assistive devices.
Clear consciousness and stable medical condition.
Willingness to participate, commit to the exercise protocol, and provide signed informed consent.
Proficiency in using a smartphone.
Exclusion Criteria:
- Presence of metal implants, such as cardiac pacemakers, stents, steel plates, or artificial joints (due to BIA measurement constraints).
Cognitive impairment, epilepsy, other neurological disorders, or severe mental illness that prevents cooperation with the study.
Inability to complete the exercise intervention due to severe cardiovascular or musculoskeletal diseases.
Severe organ dysfunction (e.g., heart failure), organ failure, or active infection.
Inability to maintain adherence or significant missing data (participants who withdraw or are lost to follow-up).
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし：Waitlist Control Group
Participants will maintain their usual routine for the first 3 months.
After the primary endpoint assessment at month 3, they will cross over to receive the identical 12-week resistance exercise program.
|
|
|
実験的：Resistance Training Group
Participants in this group will receive the BCW-based resistance exercise program immediately for 12 weeks (twice weekly).
|
Structured 12-week resistance exercise (RE) program based on the Behavior Change Wheel (BCW) and COM-B model. Theory (BCW): Capability is enhanced via sarcopenia education and face-to-face instruction. Opportunity is facilitated by providing free resistance bands, training venues, and peer demonstrations. Motivation is sustained via a points-based reward system, social commendations, and phone/alarm reminders. Protocol (FITT): Frequency: 2 supervised sessions/week (>=48h apart). Time: 60-min sessions (meditation, warm-up, RE, stretching). Intensity: Progressive loading from 40%-50% up to 70% of 1RM using color-coded bands. Progressions (+5% 1RM) guided by Borg RPE (12-14). Type: Multi-component RE (chest, back, shoulders, glutes, lower body, core) doing 1-2 sets of 10 reps with 60-90s rest. Safety: Vitals (BP, HR) are recorded pre- and post-session. Continuous symptom monitoring prevents adverse events. No fasting exercise permitted. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Skeletal Muscle Mass Index
時間枠：Baseline, 3 months, and 6 months
|
Skeletal muscle mass will be measured using Bioelectrical Impedance Analysis (BIA).
SMI is calculated as appendicular skeletal muscle mass (ASM) divided by height squared (kg/m²).
|
Baseline, 3 months, and 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Handgrip Strength
時間枠：Baseline, Month 3, and Month 6
|
Measured in kilograms (kg) using an electronic handgrip dynamometer.
Participants stand with arms hanging naturally and squeeze the device with their dominant hand with maximum effort.
The test is performed twice with a 1-minute interval, and the maximum value is recorded.
|
Baseline, Month 3, and Month 6
|
|
6-Meter Gait Speed
時間枠：Baseline, Month 3, and Month 6
|
Calculated in meters per second (m/s).
Participants walk at a usual pace over a 6-meter distance.
The test is conducted at least twice, and the average value is used to evaluate physical performance.
|
Baseline, Month 3, and Month 6
|
|
Self-Efficacy for Exercise Scale - Chinese Version (SEE-C) Score
時間枠：Baseline, Month 3, and Month 6
|
Assessed using the 9-item Chinese version of the SEE scale.
Each item is rated from 0 (no confidence) to 10 (total confidence).
The total score is the sum of all items divided by 9. Higher scores indicate higher exercise self-efficacy.
|
Baseline, Month 3, and Month 6
|
|
Exercise Adherence Rate
時間枠：Month 3 (Experimental Group) and Month 6 (Waitlist Group)
|
Expressed as the ratio of actual exercise sessions attended to the planned sessions.
Good adherence is defined as completing 80% or more of the scheduled sessions over the 12-week intervention period.
|
Month 3 (Experimental Group) and Month 6 (Waitlist Group)
|
|
Sarcopenia Quality of Life (SarQoL) Questionnaire Score
時間枠：Baseline, Month 3, and Month 6
|
Assessed using the Chinese(Mandarin) version of the Sarcopenia Quality of Life (SarQoL) questionnaire.
It specifically evaluates the quality of life in older adults with sarcopenia across multiple domains.
Scores range from 0 to 100, with higher scores representing better quality of life.
|
Baseline, Month 3, and Month 6
|
|
Participant satisfaction
時間枠：Month 3 (Experimental Group) and Month 6 (Waitlist Group)
|
The questionnaire will cover four domains, including satisfaction with the exercise program, instructor support, facility conditions, and overall perceived benefit.
Each item will be rated on a 5-point Likert scale (1 = very dissatisfied to 5 = very satisfied), and the mean score will be calculated, with higher scores indicating greater satisfaction.
|
Month 3 (Experimental Group) and Month 6 (Waitlist Group)
|
協力者と研究者
捜査官
- 主任研究者：Xuejiao Zhu, PhD、Hangzhou Normal University
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2026017
- YJSYC202603152 (その他の助成金/資金番号：Hangzhou Normal University)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。